-
Suffolk University Law School, J.D.
magna cum laude
-
Rensselaer Polytechnic Institute, M.S.E.
Electrical Engineering
-
Rensselaer Polytechnic Institute, B.S.
Biomedical Engineering
- U.S. Patent and Trademark Office
- U.S. District Court, Massachusetts
-
American Bar Association
- Boston Bar Association
|
Richard B. Smith, a partner in our Business Law Department, serves as counsel to public and private life sciences companies, advising those companies on strategic business collaborations involving licensing, research, development, marketing, supply, clinical research and co-promotion transactions. Richard also advises companies on other corporate issues common to life science companies, including corporate formation for start-up ventures, venture capital and other financing, joint ventures, mergers and acquisitions, university licensing and intellectual property strategies. Richard is also a registered patent attorney.
Examples of recent life science engagements:
- Represented a Dutch biopharmaceutical company in a strategic collaboration with a major pharmaceutical company involving oligonucleotide therapeutic products for an orphan drug indication in a deal valued at over $650 million.
- Represented a publicly held biopharmaceutical company in an strategic license and development deal with a major pharmaceutical company involving a therapeutic cancer vaccine in a deal valued at over $440 million.
- Advised a publicly held biopharmaceutical company in the purchase of certain biotech products from a large publicly held biotechnology company.
- Advised a privately held German biotechnology company in its merger with a privately held U.S. biotechnology company.
- Represented a privately held biotechnology company in its license of a therapeutic pharmaceutical product from a small Japanese company.
- Advised a privately held specialty pharmaceutical company in a strategic collaboration with a major Japanese company involving a small molecule therapeutic product.
- Advised a human diagnostics company on its license of molecular diagnostics from a large publicly held company.
- Advised a privately held medical device company in its strategic collaboration with a major medical device company.
- Represented biopharmaceutical and specialty pharmaceutical companies in strategic collaborations with major biotechnology and pharmaceutical companies involving technologies such as antibody complex anti-infectives, small molecule therapeutics, oligonucleotides, RNAi and antisense.
Richard B. Smith, a partner in our Business Law Department, serves as counsel to public and private life sciences companies, advising those companies on strategic business collaborations involving licensing, research, development, marketing, supply, clinical research and co-promotion transactions. Richard also advises companies on other corporate issues common to life science companies, including corporate formation for start-up ventures, venture capital and other financing, joint ventures, mergers and acquisitions, university licensing and intellectual property strategies. Richard is also a registered patent attorney. Examples of recent life science engagements:- Represented a Dutch biopharmaceutical company in a strategic collaboration with a major pharmaceutical company involving oligonucleotide therapeutic products for an orphan drug indication in a deal valued at over $650 million.
- Represented a publicly held biopharmaceutical company in an strategic license and development deal with a major pharmaceutical company involving a therapeutic cancer vaccine in a deal valued at over $440 million.
- Advised a publicly held biopharmaceutical company in the purchase of certain biotech products from a large publicly held biotechnology company.
- Advised a privately held German biotechnology company in its merger with a privately held U.S. biotechnology company.
- Represented a privately held biotechnology company in its license of a therapeutic pharmaceutical product from a small Japanese company.
- Advised a privately held specialty pharmaceutical company in a strategic collaboration with a major Japanese company involving a small molecule therapeutic product.
- Advised a human diagnostics company on its license of molecular diagnostics from a large publicly held company.
- Advised a privately held medical device company in its strategic collaboration with a major medical device company.
- Represented biopharmaceutical and specialty pharmaceutical companies in strategic collaborations with major biotechnology and pharmaceutical companies involving technologies such as antibody complex anti-infectives, small molecule therapeutics, oligonucleotides, RNAi and antisense.
Recent Speaking Engagements and Publications
Speaking Engagements
- 2010 - Medical Devices Summit 2010 - Maximizing the Value of Your IP Portfolio and Safeguarding Product IP Ownership, Speaker.
- 2009 - Therapeutic Area Partnerships Conference - Structuring and Negotiating Collaborative Agreements in View of Follow-on Biologics, Speaker.
- 2009 - 19th Annual Pharmaceutical Strategic Alliances Conference - In-Licensing from Established Pharma: Has It Worked?, Panel moderator
- 2008 CHI Drug Repositioning Summit - Drug Repositioning: Selecting the Right Business Model and Partner, Speaker
- 2008 Marcus Evans Drug Repositioning and R&D Enhancement Conference - Integrating Intellectual Property and Regulatory Strategies to Protect Repositioned Drugs, Speaker
- 2008 – Windhover Pharmaceutical Strategic Outlook Conference – Funding the Pipeline, Panel moderator and speaker
- 2008 - 18th Annual Windhover Pharmaceutical Strategic Alliance Conference
- 2007 MedTech Insight Conference – Riding the Wave of Patent Reform, Moderator and Speaker
- 2007 GTC Imaging and Drug Discovery Conference – Commercialization of Research Tools, Speaker
- 2007 CHI Annual Drug Repositioning Summit – IP and Practical Issues of Drug Repositioning and Repurposing, Panelist
- 2007 – M.I.T. Innovation Series - Medical Devices: Executing on the Vision, Organizer and Moderator
- 2007 Florida Tech Transfer Conference – Recent Developments in Patent Law, Speaker
- Patent Resource Group’s (PRG) Patent Counsel's Vital Role in Corporate Transactions – Course Faculty
- E.A.P.D. Program - Avoiding Crashes at the Patent-Antitrust Intersection, Speaker
- E.A.P.D. Intellectual Property Bulletin – The Supreme Court Shifts the Patent Licensing Landscape, Author
- Genetic Engineering News – Licensees May be Gaining a New Legal Weapon, Author
Before Edwards Angell Palmer & Dodge
After graduating from the Rensselaer Polytechnic Institute with an undergraduate degree in Biomedical Engineering and a Master's degree in Electrical Engineering, Mr. Smith worked as an engineer for the Hewlett-Packard Company for nine years and was primarily involved with the design and manufacturing of cardiac ultrasound imaging equipment. He holds three patents related to his work at Hewlett-Packard.
|
|